Editing test page
Jump to navigation
Jump to search
Carboplatin & Paclitaxel (CP) & Nivolumab
CP & Nivolumab: Carboplatin, Paclitaxel, Nivolumab
Regimen variant #1, 5/175/360
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | ||
---|---|---|---|---|---|---|
Forde et al. 2022 (CheckMate 816)
|
2017-2019 | Phase 3 (E-RT-esc) | 1a. CP 1b. CVb 1c. DC |
Superior EFS (co-primary endpoint) Median EFS: 31.6 vs 20.8 mo (HR 0.63, 97.38% CI 0.43-0.91) Superior pCR rate (co-primary endpoint) pCR rate: 24% vs 2.2% (OR 13.94, 99% CI 3.49-55.75) |
Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details.
Biomarker eligibility criteria
- CheckMate 816: No sensitizing EGFR or ALK mutations